The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

This region encodes for the reverse transcriptase and protease enzymes, the targets of current antiretroviral drugs. Specific gene sequences are compared with that of a reference (wild-type ...

Drug regimens now offer more potent, less toxic and more durable choices in the treatment of HIV disease than ever before. This has led to a need to consider the convenient, sequential use of ...

Biktarvy is a complete treatment for HIV. This means you take the medication by itself, without other antiretroviral drugs (drugs used to treat HIV). If you have trouble swallowing tablets ...

The antiretroviral drug has been hailed as a potential game-changer in the fight against HIV, with early trials finding the treatment 100 percent effective in preventing HIV infection. With ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

Anemia prevalence was high in adult patients with HIV infection on HAART, with female sex, older age, and nonsuppressed viral load status identified as significant predictors.

Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...

Sweden has surpassed the UNAIDS 95-95-95 targets, with reduced HIV incidence and a steady increase in diagnosed and treated ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...